Study on the Effectiveness and Safety of Telitacicept Combined with Tofacitinib for Adults with Difficult-to-Treat Rheumatoid Arthritis

What this Trial Is About

Researchers are evaluating the clinical effectiveness and safety of combining telitacicept with tofacitinib in patients who have refractory rheumatoid arthritis that has not responded to other treatments. The study focuses on patients who meet the 2021 EULAR diagnostic criteria and have previously tried traditional and biological disease-modifying anti-rheumatic drugs without success. Participants receive a combined treatment of telitacicept and tofacitinib. This is an observational study monitoring real-world patients who require this combination therapy due to inadequate response to other medications. The study will assess treatment effects and safety over a maximum period of one year. During the study, participants will be monitored for treatment effectiveness and any adverse events. Researchers will evaluate clinical outcomes related to rheumatoid arthritis and track the incidence of treatment-emergent adverse events. The study spans up to one year of observation to gather comprehensive safety and efficacy data.

Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis